Threshold Pharmaceuticals, Inc (NASDAQ:THLD), a biotechnology company, engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer. The products from Threshold Pharmaceuticals include TH-302, a novel drug candidate which is in Phase 1, Phase 1/2, and Phase 2 clinical trials for cancer.